Category Archives: Public Policy

Latest From Public Policy

2011 BIO International event spotlights expert feedback on regulatory strategy

Our good friend John Carroll, blogs on the free ranging discussion he will be hosting during the 2011 BIO International Convention, and tackling one of the most complex issues of the day for biopharma companies. You can send your questions to the panel of experts discussing the issues. In the meantime, you can also email John if there are any regulatory issues you are interested on discussing.

Events, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,

Debunking the Myth: Your Genes are Patented

MYTH: YOUR GENES ARE PATENTED. FACTS: IT IS NOT POSSIBLE TO PATENT YOUR GENES The term “gene patent” is a misnomer, because genes as they exist in the body cannot be patented. Because a naturally-occurring gene – even a newly-discovered one – cannot be patented, patents don’t provide ownership rights over our genes, and nobody can infringe a patent by having a certain gene, or by passing it on to their children. If genes aren’t Read More >

Patently BIOtech  |  2 Comments  |  Email This Post
Tags: , , , , , , , , , ,

USPTO Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting

Biotechnology/Chemical/Pharmaceutical Customer Partnership Wednesday, June 8, 2011 Meeting Madison Auditorium Starting Time of 10:00 AM United States Patent and Trademark Office Alexandria, Virginia 600 Dulany Street, Alexandria, VA, Accessing the event: Double click on the link below (or copy it into your internet browser) https://uspto.connectsolutions.com/r80345544/ Click here for detailed login instructions in MS Word. Driving & Metro Directions /Hotels (Word)   Campus Map (html)   Campus Map (Power Point) Morning Session 10:00 – 10:30 AM. Greetings, TC Update Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

BIO’s “What Every State Should Know About Bayh-Dole” Webinar

Vaccines Research - Novartis AG

The Biotechnology Industry Organization (BIO) recently hosted a webinar entitled: “What Every State Should Know About Bayh-Dole: Leveraging University Research to Create Jobs and Spur Economic Development Benefits.” The Bayh-Dole Act, enacted in 1980, placed patent ownership of federally funded research at universities in the hands of the university and enabled universities to out-license technologies for commercialization.  As a result of the Act, more than 7200 companies were created (including nearly 600 last year despite Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Huffington Post: Data Exclusivity: Getting the Balance Right

Huffington Post: Data Exclusivity: Getting the Balance Right      A great article on the downsides of cutting or removing data exclusivity provisions for biologics.  The article points out that data protection is needed to enhance safety and create incentives to research and produce new innovative drugs that cost billions of dollars.  However, the author argues that the period must be limited somehow (not 50 years) to ensure generics can entire the market and lower costs.    Finally, the author states that lowering the data exclusivity Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,